Prognosing mortality in patients with chronic kidney disease by detecting macrophage inhibitory cytokine-1 (MIC-1)
AssigneeSt. Vincent's Hospital Sydney Limited
InventorsSamuel Norbert Breit, David Alexander Brown
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytoking-1 (MID-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.
Claims2
A method of treating a human subject with chronic kidney disease (CKD) for which the subject is receiving therapy, the method comprising:
- determining that the subject has an increased likelihood of death from all cause mortality within a period of 3 years by detecting an elevated amount of macrophage inhibitory cytokine (MIC-1) in a test serum or plasma sample from said subject as compared to the amount of MIC-1 in a sample from the subject at an earlier time point, and
- treating the subject by additional renal replacement therapy (RRT), administration of erythropoietin, vitamin D3,or calcium and/or phosphate binders, or kidney transplantation.
A method of treating a human subject with chronic kidney disease (CKD) for which the subject is receiving therapy, the method comprising:
- determining that the subject has an increased likelihood of death from all cause mortality within a period of 1 year by detecting an elevated amount of macrophage inhibitory cytokine (MIC-1) in a test serum or plasma sample from said subject as compared to the amount of MIC-1 in a sample from the subject at an earlier time point,
- treating the subject by additional renal replacement therapy (RRT), administration of erythropoietin, vitamin D3, or calcium and/or phosphate binders, or kidney transplantation.
Dependencies are inferred from the claim text.